RU2018110622A - PHARMACEUTICAL COMPOSITION CONTAINING GMG-COA REDUCTASE INHIBITOR AND ACE INHIBITOR - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING GMG-COA REDUCTASE INHIBITOR AND ACE INHIBITOR Download PDF

Info

Publication number
RU2018110622A
RU2018110622A RU2018110622A RU2018110622A RU2018110622A RU 2018110622 A RU2018110622 A RU 2018110622A RU 2018110622 A RU2018110622 A RU 2018110622A RU 2018110622 A RU2018110622 A RU 2018110622A RU 2018110622 A RU2018110622 A RU 2018110622A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
perindopril
fixed pharmaceutical
acceptable salts
Prior art date
Application number
RU2018110622A
Other languages
Russian (ru)
Other versions
RU2750934C2 (en
RU2018110622A3 (en
Inventor
Жиль Фонкнехтен
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of RU2018110622A publication Critical patent/RU2018110622A/en
Publication of RU2018110622A3 publication Critical patent/RU2018110622A3/ru
Application granted granted Critical
Publication of RU2750934C2 publication Critical patent/RU2750934C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Claims (23)

1. Фиксированная фармацевтическая композиция, содержащая аторвастатин и его фармацевтически приемлемые соли и, периндоприл и его фармацевтически приемлемые соли в комбинации с одним или несколькими фармацевтически приемлемыми вспомогательными веществами, их гидраты и их кристаллические формы.1. A fixed pharmaceutical composition comprising atorvastatin and its pharmaceutically acceptable salts and, perindopril and its pharmaceutically acceptable salts in combination with one or more pharmaceutically acceptable excipients, their hydrates and their crystalline forms. 2. Фиксированная фармацевтическая композиция по п. 1, дополнительно содержащая аспирин и его фармацевтически приемлемые соли, или индапамид и его фармацевтически приемлемые соли в комбинации с одним или несколькими фармацевтически приемлемыми вспомогательными веществами, их гидраты и их кристаллические формы.2. The fixed pharmaceutical composition according to claim 1, further comprising aspirin and its pharmaceutically acceptable salts, or indapamide and its pharmaceutically acceptable salts in combination with one or more pharmaceutically acceptable excipients, their hydrates and their crystalline forms. 3. Фиксированная фармацевтическая композиция по одному из пп. 1 или 2, в которой фармацевтическая композиция представляет собой желатиновую капсулу.3. The fixed pharmaceutical composition according to one of paragraphs. 1 or 2, in which the pharmaceutical composition is a gelatin capsule. 4. Фиксированная фармацевтическая композиция по одному из пп. 1-3, в которой:4. The fixed pharmaceutical composition according to one of paragraphs. 1-3, in which: - аторвастатин и его фармацевтически приемлемые соли или,- atorvastatin and its pharmaceutically acceptable salts or, - периндоприл и его фармацевтически приемлемые соли или,- perindopril and its pharmaceutically acceptable salts or, - индапамид и его фармацевтически приемлемые соли- indapamide and its pharmaceutically acceptable salts каждый находятся в виде минигранул.each are in the form of mini-granules. 5. Фиксированная фармацевтическая композиция по одному из пп. 2 или 3, в которой аспирин и его фармацевтически приемлемые соли находится в виде устойчивой к действию желудочного сока таблетки.5. The fixed pharmaceutical composition according to one of paragraphs. 2 or 3, wherein the aspirin and its pharmaceutically acceptable salts are in the form of a gastric acid resistant tablet. 6. Фиксированная фармацевтическая композиция по одному из пп. 1-5, в которой аторвастатин находится в виде аторвастатина кальция.6. The fixed pharmaceutical composition according to one of paragraphs. 1-5, in which atorvastatin is in the form of atorvastatin calcium. 7. Фиксированная фармацевтическая композиция по одному из пп. 1-5, в которой периндоприл находится в виде периндоприла трет-бутиламина или периндоприла аргинина и более предпочтительно в виде периндоприла аргинина.7. The fixed pharmaceutical composition according to one of paragraphs. 1-5, in which perindopril is in the form of perindopril tert-butylamine or perindopril arginine, and more preferably in the form of perindopril arginine. 8. Фиксированная фармацевтическая композиция по одному из пп. 1-7, в которой:8. The fixed pharmaceutical composition according to one of paragraphs. 1-7, in which: - дозы аторвастатина варьируются от 10 мг до 80 мг в пересчете на основание аторвастатина или от 10,80 мг до 86,80 мг в пересчете на аторвастатина кальция тригидрат,- doses of atorvastatin range from 10 mg to 80 mg, calculated on the basis of atorvastatin, or from 10.80 mg to 86.80 mg, calculated on atorvastatin calcium trihydrate, - дозы периндоприла варьируются от 1,65 мг до 9,512 мг в пересчете на основание периндоприла или от 2,5 мг до 14 мг в пересчете на периндоприла аргинин,- doses of perindopril vary from 1.65 mg to 9.512 mg, calculated on the basis of perindopril, or from 2.5 mg to 14 mg, calculated on the basis of perindopril arginine, - дозы аспирина составляют от 75 мг до 150 мг в пересчете на основание аспирина,- doses of aspirin are from 75 mg to 150 mg, calculated on the basis of aspirin, - дозы индапамида варьируются от 0,625 мг до 2,5 мг в пересчете на основание индапамида.- doses of indapamide range from 0.625 mg to 2.5 mg, calculated on the basis of indapamide. 9. Фиксированная фармацевтическая композиция по одному из пп. 1-8, в которой дозы:9. The fixed pharmaceutical composition according to one of paragraphs. 1-8, in which the dose: - аторвастатина кальция составляют 10 мг, 20 мг, 40 мг и 80 мг,- atorvastatin calcium is 10 mg, 20 mg, 40 mg and 80 mg, - периндоприла аргинина составляют 2,5 мг, 3,5 мг, 5 мг, 7 мг, 10 мг и 14 мг,- perindopril arginine are 2.5 mg, 3.5 mg, 5 mg, 7 mg, 10 mg and 14 mg, - аспирина составляют 75 мг, 100 мг и 150 мг,- aspirin is 75 mg, 100 mg and 150 mg, - индапамида составляют 0,625 мг, 1,25 мг, 1,5 мг и 2,5 мг.- indapamide are 0.625 mg, 1.25 mg, 1.5 mg and 2.5 mg. 10. Фиксированные фармацевтические композиции по одному из пп. 1-9 для применения в лечении и профилактике сердечно-сосудистых заболеваний.10. Fixed pharmaceutical compositions according to one of claims. 1-9 for use in the treatment and prevention of cardiovascular disease. 11. Фиксированные фармацевтические композиции по п. 10, отличающиеся тем, что сердечно-сосудистые заболевания выбирают из коронарных осложнений у пациентов с инфарктом миокарда в анамнезе и/или реваскуляризацией в сочетании с первичной гиперхолестеринемией или смешанной гиперлипидемией.11. Fixed pharmaceutical compositions according to claim 10, characterized in that the cardiovascular diseases are selected from coronary complications in patients with a history of myocardial infarction and / or revascularization in combination with primary hypercholesterolemia or mixed hyperlipidemia.
RU2018110622A 2015-08-27 2016-08-26 PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND ACE INHIBITOR RU2750934C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1570030A FR3040303B1 (en) 2015-08-27 2015-08-27 PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITOR AND ECA INHIBITOR
FR1570030 2015-08-27
PCT/FR2016/052126 WO2017032953A1 (en) 2015-08-27 2016-08-26 Pharmaceutical composition comprising an hmg-coa reductase inhibitor and an eca inhibitor

Publications (3)

Publication Number Publication Date
RU2018110622A true RU2018110622A (en) 2019-09-27
RU2018110622A3 RU2018110622A3 (en) 2020-01-31
RU2750934C2 RU2750934C2 (en) 2021-07-06

Family

ID=54708062

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018110622A RU2750934C2 (en) 2015-08-27 2016-08-26 PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND ACE INHIBITOR

Country Status (15)

Country Link
EP (1) EP3340980A1 (en)
KR (1) KR20180041233A (en)
CN (1) CN108135882A (en)
BR (1) BR112018003392A2 (en)
EA (1) EA038261B1 (en)
FR (1) FR3040303B1 (en)
GE (1) GEP20207170B (en)
MA (1) MA42696A (en)
MX (1) MX2018002373A (en)
PH (1) PH12018500370A1 (en)
RU (1) RU2750934C2 (en)
SG (2) SG10202000597UA (en)
TN (1) TN2018000055A1 (en)
UA (1) UA122908C2 (en)
WO (1) WO2017032953A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102245273B1 (en) * 2019-03-15 2021-04-28 서울대학교병원 Composition for preventing or treating cardiometabolic syndrome comprising noranhydroicaritin
EP3842035A1 (en) 2019-12-23 2021-06-30 KRKA, d.d., Novo mesto Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
FR2838648B1 (en) * 2002-04-18 2004-05-21 Servier Lab NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
WO2004080488A2 (en) * 2003-03-10 2004-09-23 Bayer Healthcare Ag Combined preparations of acetyl salicylic acid with an hmg-coa reductase inhibitor
PL2120878T3 (en) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd A dosage form containing two active pharmaceutical ingredients in different physical forms
JP2011510067A (en) * 2008-01-25 2011-03-31 トレント・ファーマシューティカルズ・リミテッド Combination medicine
CN101612403A (en) * 2009-08-13 2009-12-30 王丽燕 The pharmaceutical composition that contains calcium antagonist, ACE inhibitor and statins
CN101791297B (en) * 2010-02-10 2012-03-28 中国药科大学 Atorvastatin calcium oral disintegrating tablet and preparation method thereof

Also Published As

Publication number Publication date
KR20180041233A (en) 2018-04-23
EA201890591A1 (en) 2018-09-28
MX2018002373A (en) 2018-07-06
RU2750934C2 (en) 2021-07-06
FR3040303A1 (en) 2017-03-03
UA122908C2 (en) 2021-01-20
CN108135882A (en) 2018-06-08
EA038261B1 (en) 2021-07-30
FR3040303B1 (en) 2019-04-05
BR112018003392A2 (en) 2018-09-25
MA42696A (en) 2018-07-04
PH12018500370A1 (en) 2018-08-29
RU2018110622A3 (en) 2020-01-31
SG11201801382UA (en) 2018-03-28
SG10202000597UA (en) 2020-03-30
GEP20207170B (en) 2020-10-12
TN2018000055A1 (en) 2019-07-08
WO2017032953A1 (en) 2017-03-02
EP3340980A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
EA201890654A1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF THE HUMAN IMMUNODEFICIENCY VIRUS
EA201992116A1 (en) PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
CY1120467T1 (en) DISTRIBUTED IN ORAL DOSAGE UNIT CONTAINING AN OSTETROL COMPONENT
RU2017106896A (en) ANTIMETANOGENIC COMPOSITIONS AND THEIR APPLICATION
AR081032A1 (en) PHARMACEUTICAL FORMULATION IN THE FORM OF TWO-COATED TABLETS THAT INCLUDE INHIBITOR OF HMG-COA REDUCTASA AND IRBESARTAN
HRP20230267T1 (en) Compositions for the treatment of hypertension
EA201600486A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANTIKOAGULANT N- (5-CHLORPYRIDIN-2-IL) -2 - ({4- [ETHANIMIDOIL (METHYL) AMINO] BENZOIL} AMINO) -5-METHYLBENZAMIDE
RU2018110622A (en) PHARMACEUTICAL COMPOSITION CONTAINING GMG-COA REDUCTASE INHIBITOR AND ACE INHIBITOR
EA202192118A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ACETAMINOPHEN AND IBUPROFEN
RU2018140193A (en) PHARMACEUTICAL COMPOSITION CONTAINING A BETA-BLOCKER, A CONVERSING ENZYME INHIBITOR AND A HYPOTENSIVE OR NIPA
RU2017120028A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERLIPIDIMIA
RU2012136190A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT
RU2017115341A (en) PHARMACEUTICAL COMPOSITION CONTAINING A BETA BLOCKER AND ANGIOTENSIN-CONVERTER ENZYME INHIBITOR
RU2016107372A (en) STRENGTHENING OF METOTREXATE EFFECT BY COMBINED USE WITH LIPOPHILIC STATINS
JP2017509683A5 (en)
RU2017113827A (en) PHARMACEUTICAL COMPOSITION FOR REDUCING SPASES OF THE BLADDER AND METHOD OF ITS APPLICATION
RU2017129085A (en) New N-carbamoylmethyl-4-phenyl-2-pyrrolidone formulation
RU2017140269A (en) NEW POLYMORPHIC FORMS OF TRIMEBUTIN MALEAT, METHOD OF OBTAINING AND APPLICATION
EA202091611A2 (en) FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID
WO2020175922A3 (en) Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
RU2015121239A (en) COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING PAIN SYNDROMES
JP2018513862A5 (en)
EA202091610A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOSANIC ACID
RU2020101999A (en) LIKOFLIGOSIN FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS